BILLERICA, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH and Medacta International SA (collectively, ” Medacta”), which settles all patent disputes between the companies.

“We are pleased to have resolved all ongoing patent litigation related to the Medacta dispute,” said Mark Augusti, President and Chief Executive Officer. “Through this settlement, we have once again monetized our patient-specific instrument patents and have steadfastly protected our patient-specific implant products and services. This further underscores the value of giving surgeons the ability to incorporate patient-specific surgical planning into their procedures.”

Under the terms of the settlement, Medacta will receive a non-exclusive license to certain Conformis patents related to patient-specific instruments for use with commercially available knee and shoulder implants.

About Conform, Inc.

Founded in 2004, Conformis is a medical technology company focused on improving orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services? program, as well as data-based, standardized solutions that combine the many benefits of personalization with the convenience and… Flexibility of an off-the-shelf system. Conformis’ Just-in-Time sterile Surgery-in-a-Box™ delivery system is available with all implants and personalized single-use instruments. Conformis owns or exclusively licenses issued patents and pending patent applications covering personalized implants and patient-specific instrumentation for all major joints.

For more information visit www.conformis.com. Sign up to receive future releases in email alerts ir.conformis.com.

…